Fusion Pharmaceuticals Inc. (37) | Business Operations (9)
Browse by Subcategory
Recent Contracts
-
Amendment No. 1 to Collaboration Agreement, dated June 28, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company
(Filed With SEC on November 9, 2021)
-
Form of Officer Indemnification Agreement
(Filed With SEC on June 22, 2020)
-
Master Services Agreement, dated as of February 22, 2017, by and between the Centre for Probe Development and Commercialization Inc. and the Registrant
(Filed With SEC on June 5, 2020)
-
Collaboration Agreement, dated December 10, 2020, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company
(Filed With SEC on November 9, 2021)
-
Amendment No. 2 to Collaboration Agreement, dated July 27, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company
(Filed With SEC on November 9, 2021)
-
Amendment No. 3 to Collaboration Agreement, dated August 12, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company
(Filed With SEC on November 9, 2021)
-
Strategic Collaboration Agreement by and between Fusion Pharmaceuticals Inc. and AstraZeneca UK Limited, dated October 30, 2020
(Filed With SEC on November 2, 2020)
-
Form of Director Indemnification Agreement
(Filed With SEC on June 22, 2020)
-
Supply Agreement, dated as of January 17, 2019, by and between the Centre for Probe Development and Commercialization Inc. and the Registrant
(Filed With SEC on June 5, 2020)